Mp09-01 Temporal Trends of BPH Medications and Procedures - Contemporary Medicare Database Analysis From 2013-2020

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy (MP09) 1 May 2024MP09-01 TEMPORAL TRENDS OF BPH MEDICATIONS AND PROCEDURES - CONTEMPORARY MEDICARE DATABASE ANALYSIS FROM 2013-2020 Kevin J. Chua, Jake Drobner, John Pfail, Rachel Passarelli, Benjamin Lichtbroun, Hiren V. Patel, Elias Hyams, Sammy E. Elsamra, Danielle Velez-Leitner, and Ji Hae Park Kevin J. ChuaKevin J. Chua, Jake DrobnerJake Drobner, John PfailJohn Pfail, Rachel PassarelliRachel Passarelli, Benjamin LichtbrounBenjamin Lichtbroun, Hiren V. PatelHiren V. Patel, Elias HyamsElias Hyams, Sammy E. ElsamraSammy E. Elsamra, Danielle Velez-LeitnerDanielle Velez-Leitner, and Ji Hae ParkJi Hae Park View All Author Informationhttps: //doi. org/10. 1097/01. JU. 0001008920. 55771. 18. 01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: There has been rising usage of minimally invasive techniques for treatment of symptomatic benign prostatic hyperplasia (BPH) including water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL). We hypothesized that the increased adoption of such technologies would lead to a decrease of BPH medication prescriptions and costs. METHODS: The 2013-2020 Medicare Part D Public Use File was used to identify the number of claims and annual expenditure of alpha blockers (AB), 5-alpha reductase inhibitors (5ARI), tamsulosin-dutasteride combination pill, and tadalafil by urologists. Medicare Part B National Summary Data File was used to calculate the number of each BPH procedure per year. RESULTS: From 2013 to 2020, total BPH medication claims increased from 5, 682, 443 in 2013 to 6, 874, 329 in 2017 but decreased each year afterward to 6, 565, 868 in 2020 (Figure 1). Annual expenditure increased from 324, 545, 652 to 353, 369, 600 from 2013 to 2015, but then decreased to 167, 365, 641 by 2020 (Figure 2). Dutasteride, silodosin and tadalafil expenditure decreased by about 100, 45 and 30 million from 2014 to 2020, respectively. The number of BPH procedures decreased from 106, 016 to 100, 963 from 2013 to 2015, but then increased to 129, 958 in 2019 (Figure 1). PUL increased from 0 to 35, 639 from 2014 to 2019. WVTT increased from 0 to 7, 611 from 2017 to 2019. CONCLUSIONS: BPH medication prescribing was seen to decrease after 2017 which may demonstrate the effect of increased surgical treatment. The economic burden of BPH medications has also been decreasing over time. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc. FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e126 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc. Metrics Author Information Kevin J. Chua More articles by this author Jake Drobner More articles by this author John Pfail More articles by this author Rachel Passarelli More articles by this author Benjamin Lichtbroun More articles by this author Hiren V. Patel More articles by this author Elias Hyams More articles by this author Sammy E. Elsamra More articles by this author Danielle Velez-Leitner More articles by this author Ji Hae Park More articles by this author Expand All Advertisement PDF downloadLoading. . .